[CAS NO. 2089647-47-0] SGN-2FF
PRODUCTS SPECIFICATIONS [2089647-47-0]
DESCRIPTION [2089647-47-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 166.15 |
| Molecular Formula | C6H11FO4 |
| SMILES | F[C@H]1[C@@H]([C@@H]([C@H](C)OC1O)O)O |
Summary
SGN-2FF is a potent and orally active inhibitor of fucosylation, directly inhibits fucosyltransferase activity. SGN-2FF possesses antitumor activity [1] .
IC50 & Target
Fucosyltransferase [1]
In Vitro
SGN-2FF (2-Fluorofucose) is an inhibitor of fucosylation, inhibits cellular fucosylation by depleting the fucosylation substrate GDP-fucose, and by direct inhibition of fucosyltransferases, and leads to the production of afucosylated glycoproteins including antibodies. SGN-2FF activates human T cells in an antigen-dependent manner [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
SGN-2FF exhibits antitumor activity in multiple mouse tumor models, showing substantial tumor growth delay. SGN-2FF elevates the protective effect of a lymphoma vaccine in a syngeneic mouse model [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02952989 | Seagen Inc. |
Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Breast Neoplasms|Urinary Bladder Neoplasm|Carcinoma, Squamous Cell of Head and Neck|Colorectal Neoplasms|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
|
February 23, 2017 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 300.93 mM ; Need ultrasonic)
H 2 O : 36.67 mg/mL ( 220.70 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.0187 mL | 30.0933 mL | 60.1866 mL |
| 5 mM | 1.2037 mL | 6.0187 mL | 12.0373 mL |
| 10 mM | 0.6019 mL | 3.0093 mL | 6.0187 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (300.93 mM); Clear solution; Need ultrasonic